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Hartford, Connecticut
Is a “routine invasive” or “selective invasive” strategy the best approach for patients with
non–ST-segment elevation acute coronary syndrome (ACS)? A “selective invasive” strategy
incorporates ischemia-guided use of aggressive medical therapy followed by angiography and
revascularization for angina or stress-induced myocardial ischemia. The “routine invasive”
strategy (cardiac catheterization followed by percutaneous coronary intervention within 24 to
48 h of symptom-onset) is frequently employed, but no randomized, controlled trials have
demonstrated improved clinical outcomes. Recently, the second Fragmin and fast Revascu-
larization during InStability in Coronary artery disease (FRISC-II) and the Treat angina with
Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy–
Thrombolysis in Myocardial Infarction (TACTICS TIMI-18) trials found significant
reductions in death, recurrent myocardial infarction, or hospitalization for biomarker-positive
ACS. Also, the third Randomized Intervention Trial of unstable Angina (RITA-3) recently
reported a halving of refractory angina and reduction in the use of antianginal medication
with early intervention. Early trials failed to demonstrate the superiority of the “routine
invasive” approach, presumably because of fewer revascularizations, unavailability of stents,
and more recent use of glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins.
The FRISC-II, TACTICS TIMI-18, and RITA-3 studies indicate that higher-risk patients
benefit from early revascularization, but that aggressive antiplatelet, antithrombin, and
anti-ischemic therapy are also important. While all three trials support an “early invasive”
approach in intermediate- and high-risk patients, other trials support a more “conservative”
approach in those without electrocardiographic changes or enzyme elevations. Optimal
management should incorporate both strategies. (J Am Coll Cardiol 2003;41:113S–122S)
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Among patients who present with non–ST-segment eleva-
tion (NSTE) acute coronary syndromes (ACS), should risk
stratification be anatomy-driven or ischemia-driven? The
American College of Cardiology/American Heart Associa-
tion Task Force on Practice Guidelines has published
recommendations regarding diagnosis and treatment of
patients with known or suspected unstable angina (UA)/
NSTE myocardial infarction (NSTEMI) (1,2). The acute
ischemia pathway presented in these guidelines encom-
passes both an early invasive strategy and an early conser-
vative strategy (1) (Fig. 1). However, both the continued
technical evolution of stents and the widespread availability
and success of catheter-based revascularization have
prompted many clinicians to question the need for nonin-
vasive risk stratification of any kind. Accordingly, this
discussion will address the following four key issues: 1)
Which patients benefit from early percutaneous coronary
intervention (PCI)? 2) When is the optimal time to inter-
vene? 3) What are the relative roles of revascularization and
adjunctive pharmacologic therapy? and 4) Why do patients
benefit?
During the past two decades, PCI has become a standard
treatment option for many patients with coronary heart
disease. With the widespread acceptance of PCI and the
continued technical evolution of catheter-based procedures,
notably intracoronary stents, an increasingly aggressive ap-
proach to primary angioplasty has been adopted. In partic-
ular, this approach is commonly chosen for patients pre-
senting with ST-segment elevation MI (where the evidence
of clinical benefit from urgent primary PCI is mounting
rapidly) and for those with NSTEMI (where evidence for
urgent PCI is less well defined).
The “routine early invasive strategy” is typically defined as
cardiac catheterization followed by PCI in patients without
a clinical contraindication within the first 24 to 48 h of
presentation. Proponents of this strategy believe it is appro-
priate for all patients presenting with ACS, including those
with NSTEMI and those who are biomarker-negative.
Clinicians who favor the more invasive approach to treat-
ment tend to argue that any form of risk stratification results
in less definitive management. The rationale behind this
concept is that once coronary angiography is performed, the
cardiologist can tailor therapy more appropriately. However,
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no randomized clinical trial to date has evaluated this
strategy in NSTE ACS patients who present within 24 h of
symptom-onset.
By contrast, a “selective invasive strategy” involves aggres-
sive medical therapy (intensive antiplatelet, antithrombotic,
and anti-ischemic medications) combined with careful clin-
ical assessment and provocative testing. Such testing may
utilize exercise electrocardiography (the most commonly
performed test), nuclear myocardial perfusion scintigraphy,
dobutamine or dipyridamole stress echocardiography, phar-
macologic vasodilator stress testing, or other evaluation
methods, depending on availability, cost, and specific infor-
mation sought. This is followed by the selective use of
coronary angiography and, if necessary, revascularization for
spontaneous angina or objective evidence of stress-induced
myocardial ischemia. Whether improved clinical outcomes
can be demonstrated with an aggressive early revasculariza-
tion approach in all subsets of patients remains to be
determined, however.
RANDOMIZED STUDIES COMPARING
INVASIVE VERSUS CONSERVATIVE STRATEGIES
The TIMI-IIIB trials. The Thrombolysis in Myocardial
Ischemia (TIMI-IIIB) trials included 1,473 patients with
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
CABG  coronary artery bypass graft
CK-MB  creatine kinase-myocardial band
GP  glycoprotein
LMWH  low-molecular-weight heparin
NSTEMI  non–ST-segment elevation myocardial
infarction
PCI  percutaneous coronary intervention
RR  risk ratio
UA  unstable angina
UFH  unfractionated heparin
Figure 1. Acute ischemia pathway. EF  ejection fraction; LV  left ventricular; Rx  treatment. Adapted from ACC/AHA Guidelines for the
Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol 2000;36:970–1062. Copyright
2002 by the American College of Cardiology and American Heart Association, Inc. Permission granted for one-time use.
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UA or non–Q-wave MI (3). This trial was a 2  2 factorial
design comparing tissue plasminogen activator with placebo
and an early invasive strategy (n  740) versus a conserva-
tive strategy (n  733) within 48 h of randomization. The
invasive strategy involved cardiac catheterization, left ven-
tricular angiography, and coronary arteriography 18 to 48 h
after randomization. The PCI was performed in all lesions
with 60% stenosis. Coronary artery bypass graft (CABG)
surgery was performed in the presence of significant left
main coronary artery obstruction, three-vessel disease, and
depressed left ventricular function, or recurrent UA. The
conservative strategy involved initial medical therapy, with
intervention only after ischemia was detected on stress
testing at six weeks. All patients were treated with bed rest,
oxygen, anti-ischemic medications (beta-blockade, calcium
channel blockade, and long-acting nitrates), aspirin, and
heparin.
The primary outcome (combined death, nonfatal MI, or
ischemia on stress testing) occurred in 18.1% of patients in
the invasive-strategy group and in 16.2% of patients in the
conservative-strategy group (a nonsignificant difference)
(Table 1). Of the patients randomized to the conservative-
strategy group, ST-segment depression on the qualifying
electrocardiogram, prior aspirin use, and older age were inde-
pendent predictors of primary outcome components (3).
VANQWISH. The Veterans Affairs Non–Q-Wave In-
farction Strategies in Hospital (VANQWISH) trial (4)
compared early and late clinical outcomes (death or recur-
rent MI) in patients randomly assigned to either early
invasive strategy or conservative treatment. This trial was
the largest of its kind to test the efficacy of long-term
management strategies in patients who sustained an acute
non-Q-wave MI. As shown in Figure 2, patients treated
with the early invasive strategy (heart catheterization fol-
lowed by myocardial revascularization) had significantly
worse clinical outcomes during the first year of follow-up
than did those treated with a conservative strategy (inter-
vention guided by rigorous ischemia management, nonin-
vasive stress testing, and medical therapy). The number of
patients who had one of the components of the primary end
point was significantly higher in the invasive-strategy group
at hospital discharge (36 vs. 15 events, p  0.004), at one
month (48 vs. 26 events, p  0.012), and at one year (111
vs. 85 events, p  0.05) (4).
An overlooked feature of the VANQWISH trial is that
patients who remained in the conservative treatment arm
and did not cross over to cardiac catheterization in the 44
months of follow-up (52% of this arm) had a remarkably
low cardiac event rate; two patients (1%) died, and three
patients (1%) experienced a clinical event at 30-day
follow-up (Table 2). This low rate of events occurred in
patients with high clinical comorbidity and an almost 80%
incidence of triple-vessel and left main coronary disease.
There was no evidence of an interaction that supported
improved outcomes in the patients with the invasive strategy
(4). In contrast, the ischemia-guided strategy benefited 4 of
10 prespecified subsets of patients: those who underwent
thrombolysis; those with no prior MI; patients without
ST-segment depression; and those 60 years).
Are these results relevant to the contemporary manage-
ment of patients with NSTEMI, in light of the advances of
the last two to three years? The use of stents, the rise of
newer catheter-based techniques, and the use of glycopro-
tein (GP) IIb/IIIa receptor antagonists have expanded
rapidly (5–8). The benefits of low-molecular-weight hepa-
rins (LMWHs), particularly enoxaparin, have been convinc-
ingly demonstrated (9–11). Evidence from the Organisa-
tion to Assess Strategies for Ischemic Syndromes
(OASIS-2) trial revealed that hirudin (lepirudin), a direct
Figure 2. From the VANQWISH trial: Kaplan-Meier curves for the trial
primary end points (death or MI) at one-year of follow-up. CHR  Cox
hazard ratio; CI  confidence interval; MI  myocardial infarction;
VANQWISH  Veterans Affairs Non–Q-Wave Infarction Strategies in
Hospital. Adapted with permission from Boden WE, O’Rourke RA,
Crawford MH, et al., for the Veterans Affairs Non–Q-Wave Infarction
Strategies in Hospital (VANQWISH) trial investigators. Outcomes in
patients with acute non-Q-wave myocardial infarction randomly assigned
to an invasive as compared with a conservative management strategy.
N Engl J Med 1998;338:1785–92. Copyright © 2002, Massachusetts
Medical Society. All rights reserved.
Table 1. Invasive Versus Conservative Strategies in Patients With Non–ST-Segment Elevation
MI: Outcomes at Six Weeks in the TIMI-IIIB Trial
Invasive Strategy
(n  740)
n (%)
Conservative Strategy
(n  733)
n (%) p Value
Death 18 (2.4) 18 (2.5) NS
MI 38 (5.1) 42 (5.7) NS
Positive 6-week ETT 64 (8.6) 73 (10.0) NS
Combined 120 (16.2) 133 (18.1) NS
ETT  exercise tolerance test; MI  myocardial infarction; TIMI  Thrombolysis in Myocardial Infarction.
Permission to use data from Lippincott, Williams and Wilkins; Circulation 1994;89:1545–56.
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thrombin inhibitor, may have benefit (12). The Clopidogrel
versus Aspirin in Patients at Risk of Ischemic Events
(CAPRIE) (13) and the Clopidogrel in Unstable angina to
prevent Recurrent ischemic Events (CURE) (14) trials
showed that clopidogrel, a thienopyridine derivative similar
to ticlopidine, is an important adjunctive treatment in the
management of patients with ACS.
However, the TIMI-IIIB and VANQWISH trials are
relevant to risk stratification because they reveal that both
high- and low-risk subsets can be identified. In the
VANQWISH trial, only 9% of patients were excluded
during the first 48 to 72 h for symptoms of refractory
angina, persistent ischemia, heart failure, or significant
ventricular tachyarrhythmia or fibrillation. As discussed, the
30-day event rate of death and MI was remarkably low (1%)
with the conservative strategy, despite the high prevalence
of clinical comorbidity and angiographic morbidity.
FRISC-II. The Fragmin and Fast Revascularisation dur-
ing InStability in Coronary artery disease (FRISC-II) inva-
sive trial (15) showed, for the first time, a significant event
rate reduction favoring the invasive over the noninvasive
strategy at six months in a subset of patients with unstable
angina and non–Q-wave infarction (Fig. 3). In the trial,
2,457 patients in 58 Scandinavian hospitals were assigned to
early invasive or noninvasive treatment with placebo-
controlled LMWH (dalteparin) for three months. In the
invasive group, 96% of patients received angiography within
7 days; of those, 71% underwent revascularization within 10
days. For the noninvasive group, 10% received angiography
within seven days; of those, 9% went on to undergo
revascularization procedures. At six months, the rate of
death, MI, or both was 9.4% in the invasive group and
12.1% in the noninvasive group (risk ratio [RR], 0.78; 95%
confidence interval, 0.62 to 0.98; p  0.031) (15).
The results favoring the invasive strategy were not uni-
formly shown among patient subsets in FRISC-II, however.
In a substudy analysis of the influence of troponin levels,
42% of patients were found to be troponin-negative
(0.1 g/l) (16). The six-month rate of death or MI was
8.3% in patients assigned to an invasive strategy versus
10.3% in those assigned to a conservative strategy, a non-
significant difference.
Similarly, in the evaluation of patients who had ST-
segment deviations on the admission electrocardiogram in
FRISC-II, 418 patients had no demonstrable ST-T wave
changes (Table 3) (17). The relative risk of an unfavorable
outcome (death or MI at six months) was actually slightly
higher for patients in the invasive group. No significant
Table 2. Clinical Outcomes of Patients Who Underwent
Coronary Angiography With Revascularization or No Coronary
Angiography and No Revascularization: VANQWISH Trial
Invasive Strategy†
(With Angiography)
n  238 (52%)
Conservative Strategy‡
(No Angiography)
n  236 (52%)
30-Day event rate
Cardiac event 18 (8%) 3 (1%)
Death 12 (5%) 2 (1%)
1-Year event rate
Cardiac event 56 (24%) 26 (11%)
Death 31 (13%) 15 (6%)
VANQWISH  Veterans Affairs Non-Q-Wave Infarction Strategies in-Hospital
trial.
†After angiography; ‡After randomization.
Data derived from N Engl J Med 1999;338:1785–92.
Figure 3. From the FRISC-II trial. Kaplan-Meier analysis of the probability of event-free survival according to strategy group during six months of
follow-up for the trial primary end point of death or MI, showing significant benefit in clinical outcomes for the routine invasive strategy. CI  confidence
interval; FRISC  Fragmin and fast Revascularization during InStability in Coronary artery disease; MI  myocardial infarction; RR  risk reduction.
Adapted with permission from Elsevier Science (The Lancet 1999;354:708–15).
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benefit was shown with the invasive strategy in patients who
had isolated T-wave inversion only. The early invasive strategy
was not shown to be beneficial in fully 52% of patients who had
either no electrocardiogram changes or T-wave inversion only.
The true benefit of early invasive treatment, when evaluated by
electrocardiography, was derived from the subset of patients
with ST-segment depression MI.
In summary, patients who were troponin-negative and
those who had no ST-T-wave changes or only isolated T-wave
inversions (50% of all patients) did not benefit from an
invasive strategy. Only observational data and registry data are
available to show a reduction of death or MI, or refractory
ischemia, in NSTEMI patients who underwent PCI within
24 h of presentation. Thus, much remains to be proven with
regard to the overall benefit of applying an early aggressive
invasive strategy in such patients.
TACTICS TIMI-18. The Treat angina with Aggrastat
and determine Cost of Therapy with an Invasive or Con-
servative Strategy–TIMI-18 (TACTICS TIMI-18) trial
included 2,220 patients with UA/NSTEMI (18). Inclusion
criteria were an accelerating pattern, prolonged or recurrent
anginal pain at rest or minimal effort within the previous
24 h, plus ischemia, electrocardiogram changes, elevated
cardiac markers, or a history of prior coronary artery disease.
Study subjects were immediately treated with aspirin, hep-
arin, and the GP IIb/IIIa inhibitor tirofiban (adminis-
tered for 48 to 108 h). Patients were then randomized to
one of the following two groups: a) catheterization and
subsequent PCI/CABG within 4 to 48 h; b) conservative
strategy with catheterization performed only if objective
evidence showed recurrent ischemia or there was a
positive exercise stress test.
At six months, the primary outcome (death, MI, and
rehospitalization for ACS) occurred in 15.9% of the
invasive-strategy group and 19.4% of the conservative-
strategy group (odds ratio [OR], 0.78; p  0.025). The rate
of death or MI was also significantly lower in the invasive-
strategy group (7.3% vs. 9.5%; OR, 0.74; p 0.05) (Fig. 4).
Subgroup analysis according to troponin-T status on
admission revealed that the difference between the two
strategies was largely due to a reduction in the primary
outcome among troponin-T-positive patients. In this sub-
group, the invasive strategy was associated with a primary
outcome rate of 14.3% compared with 24.2% for the
conservative strategy (OR, 0.52; p  0.001). The two
strategies were comparable in their effects on the primary
outcome in troponin-T-negative patients. Patients with an
intermediate or high TIMI UA risk score also benefited
from an invasive over a conservative strategy. In patients
with a low TIMI UA score, the two strategies were
comparable.
RITA-3. Results from the Randomized Intervention Trial
of unstable Angina (RITA)-3 study, carried out by the
British Heart Foundation, were recently published (19).
The study compared early intervention (angiography fol-
lowed by revascularization) with a conservative strategy
(antianginal and antithrombotic medications) in 1,810
NSTE ACS patients in the United Kingdom (38% wom-
en). All patients were treated with optimal antianginal and
antiplatelet treatment, including enoxaparin. For the pri-
mary end point of death, MI, or refractory angina at four
months, there was a 9.6% risk in the intervention group
compared to 14.5% in the conservative group (RR, 0.66;
Table 3. Subset Analysis of Primary End Point by Admission Electrocardiogram in the FRISC-
II Trial
ST-T Changes n
Primary End Point (%)
Invasive vs. Noninvasive RR
(CI 95%)Noninvasive Invasive
No ST-T change 418 9.0 9.6 1.07 (0.59–1.95)
Inverted T only 866 8.5 7.7 0.90 (0.57–1.41)
ST depression 1,100 14.9 10.3 0.69 (0.50–0.95)
All patients 2,457 12.0 9.2 0.77 (0.61–0.97)
CI  confidence interval; FRISC  Fragmin and Fast Revascularization during InStability in Coronary artery disease; RR 
relative risk.
Data derived from Elsevier Science (Lancet 1999;354:708–15, and J Am Coll Cardiol 2001;37:492–8). Permission to use
data from Lippincott, Williams and Wilkins; Circulation 2001;104:2592–7.
Figure 4. From the TACTICS TIMI-18 trial. Kaplan-Meier analysis of
the probability of event-free survival for the triple composite end point of
death, MI, and biomarker-positive ACS during six months of follow-up,
showing a significant benefit for the routine invasive strategy. CI 
confidence interval; MI  myocardial infarction; OR  odds ratio;
TACTICS TIMI  Treat angina with Aggrastat and determine Cost of
Therapy with an Invasive or Conservative Strategy–Thrombolysis in
Myocardial Infarction trial. Adapted with permission from Cannon CP,
Weintraub WS, Demopoulos LA, et al., for the TACTICS–Thrombolysis
in Myocardial Infarction-18 investigators. Comparison of early invasive
and conservative strategies in patients with unstable coronary syndromes
treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med
2001;344:1879–87. Copyright © 2002, Massachusetts Medical Society.
All rights reserved.
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p 0.001), mainly attributable to a halving of the incidence
of refractory angina with the interventional strategy. (Re-
fractory angina was defined as ischemic pain at rest or on
minimum exertion, despite maximum medical treatment,
associated with new cardiographic changes prompting re-
vascularization within 24 h or readmission to hospital after
discharge.) For the co-primary end point of rates of death or
MI at one year, the results were similar for both groups, but
refractory angina and use of antianginal medications were
more significantly reduced in the early intervention group
(p  0.0006). This difference was also evident at four
months (p  0.0001) (Table 4).
A subanalysis of RITA-3 and FRISC-II found signifi-
cant reductions in the composite of death and MI in men,
but that a trend to hazard was found for early intervention
in women. Women tend to have more procedure-
related complications than men and, with equivalent
clinical presentations to men, usually have less coronary
artery disease, and therefore less to gain from an invasive
procedure.
IMPORTANCE OF ADJUNCTIVE THERAPIES
In contrast to the negative results from the TIMI-IIIB and
VANQWISH studies, the favorable results of FRISC-II,
TACTICS TIMI-18, and RITA-3 may be explained, in
part, by the fact that relative to the two earlier studies,
patients in FRISC-II and RITA-3 were treated adjunctively
with LMWH, whereas in the TACTICS TIMI-18 study,
patients were nearly universally treated with tirofiban.
Moreover, concomitant therapy with aspirin, unfractioned
heparin (UFH), intravenous nitroglycerin, and beta-
blockers was utilized for up to 96 h in TACTICS TIMI-18
or up to six days in FRISC-II. In RITA-3, aspirin,
beta-blockade, and enoxaparin were administered, and GP
IIb/IIIa inhibitors or other antiplatelet agents, nitrates, and
antithrombotic drugs were provided when appropriate. This
could have resulted in improved clinical outcomes due to the
induction of a state of intracoronary “plaque passivation”
from the combined effects of antiplatelet, antithrombin, and
anti-ischemic therapy.
Table 4. Overview of Three Randomized Trials Comparing Early Invasive With Early Noninvasive Strategy in Unstable Coronary
Artery Disease
RITA-3 TACTICS FRISC-II
No. of Patients 1,810 2,220 2,457
Time Period 1997–2001 1997–1999 1996–1998
Baseline Findings on admission
Inclusion diagnosis UA NSTEMI/UA NSTEMI/UA
Median age (yrs) 62 62 65
Female (%) 38 34 31
Diabetes mellitus (%) 13 28 12
Previous MI (%) 28 39 22
ST-depression 37 39 46
Biochemical market elevation (%) 18 37 57
Angiography Ninv Inv Ninv Inv Ninv Inv
Before discharge to 7 days (%) 16 96 51 97 10 96
6 to 12 months (%) 48 97 61 98 47 98
Coronary vessel disease
0 (%) – 22 – 13 – 14
1 (%) – 33 – – – 30
2 (%) – 24 – – – 26
3 LMD (%) – 22 – 43 – 31
Revascularization
Before discharge to 10 days (%) 10 44 36 60 9 71
Within 6 to 12 months (%) 28 57 44 61 43 78
CABG 6 to 12 months (%) 12 21 16 22 23 37
PCI 6 to 12 months (%) 16 36 28 40 20 41
Nonrevascularization, 1–3 vd, 10 days (%) – 34 – 27 – 15
Nonrevascularization, 1–3 vd, 12 months (%) – 21 – 26 – 8
Outcome 6 to 12 months
Death, MI, or severe angina leading to
readmission/revascularization (%)
14.5 9.6 19.4 15.9 42.2 13.2
Death or MI in all patients (%) 8.3 7.6 9.5 7.3 14.1 10.4
Death or MI in men (%) 10.1 7.0 – – 15.8 9.6
Death or MI in women (%) 5.1 8.6 – – 10.5 12.4
Death (%) 3.9 4.6 3.5 3.3 3.9 2.2
Spontaneous MI (%) 5.7 3.3 – – 11.3 4.2
Procedure-related MI (%) 0.4 1.7 – – 2.1 5.4
CABG  coronary artery bypass grafting; Inv  invasive; LMD  left main coronary artery disease; MI  myocardial infarction; Ninv  noninvasive; NSTEMI 
non–ST-elevation myocardial infarction; PCI  percutaneous coronary intervention; UA  unstable angina; vd  vessel disease.
Reprinted with permission from Elsevier Science (The Lancet 2002;360:743–4).
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Furthermore, stents were utilized liberally among patients
undergoing revascularization in both FRISC-II (65% of
patients) and TACTICS TIMI-18 (84%), whereas neither
of these advanced antithrombotic therapies nor stents were
available at the time of TIMI-IIIB or VANQWISH.
Unlike the FRISC-II study, no “early hazard” was noted
among patients managed invasively in the TACTICS–
TIMI-18 study. Tirofiban may have not only reduced the
incidence of early recurrent ischemic events (20,21) but also
may have attenuated myocardial necrosis resulting from
incomplete or inadequate platelet inhibition occurring dur-
ing attempts at percutaneous coronary revascularization
(22–26).
CLINICAL RISK FACTORS AND RESPONSE TO
THERAPY WITH GP IIb/IIIa RECEPTOR ANTAGONISTS
Careful assessment of patients with NSTE ACS should
help to identify patients with high-risk clinical presentations
(Table 5) and, in addition, contribute to therapeutic deci-
sion making. By using both clinical information (history,
physical, electrocardiogram results) and biochemical meth-
ods (serum cardiac markers), risk-stratification for ischemic
complications in NSTE ACS patients can be reliably
established, including the likelihood of recurrent instability,
progression to MI, or even death (27–30). This approach
can also ensure the optimal selection of therapeutic inter-
ventions for NSTE ACS patients, predicting the benefits of
intravenous platelet GP IIb/IIIa receptor antagonism, or
routine early invasive strategies.
The use of clinical risk scores to predict GP IIb/IIIa
response was demonstrated in recently published data from
two substudies of the Platelet Receptor Inhibition for
Ischemic Syndrome Management in Patients Limited by
Unstable Signs and symptoms (PRISM-PLUS) trial. Using
an exploratory analysis of clinical factors associated with
patients from PRISM-PLUS, Sabatine and colleagues (28)
identified five clinical variables that could be used in an
additive fashion to identify expected benefits to patients
from the use of tirofiban. These variables were advanced
age, prior aspirin use, prior beta-blocker use, prior CABG,
or ST-segment depression on the presenting electrocardio-
gram. Patients with 0 to 1 risk factors accrued no benefit;
those with 2 or 3 risk factors accrued intermediate benefit;
patients with 4 or 5 risk factors gained the most benefit.
Similarly, Morrow and colleagues (31) identified seven
additive risk factors in developing the TIMI Risk Score: age
65 years, prior history of CAD, 3 coronary risk factors,
ST-segment deviation, prior aspirin use within seven days,
frequent angina, or elevated serum markers of myocardial
necrosis. Using this Risk Score, they were able to predict the
benefits of therapy with tirofiban in PRISM-PLUS, which
were particularly strong in patients with scores 4.
SERUM MARKERS AND RESPONSE TO
THERAPY WITH GP IIb/IIIa RECEPTOR ANTAGONISTS
Hamm and colleagues (32), in the Chimeric c7E3 Anti-
Platelet Therapy in Unstable angina Refractory to standard
treatment trial (CAPTURE) study, were the first to use
serum markers of myocardial necrosis to identify patients
who might benefit from treatment with GP IIb/IIIa recep-
tor antagonists. Elevated serum troponin levels were later
shown, in PRISM (33), Platelet IIb/IIIa Antagonism for
the Reduction of Acute coronary syndrome events in a
Global Organization Network (PARAGON B) (34), and
PRISM-PLUS (6), to be associated with patients at partic-
ularly high risk for ischemic complications and who are
likely to benefit most from intravenous GP IIb/IIIa receptor
antagonism (Table 6). A notable exception to these data is
the result from Global Use of Strategies To Open occluded
arteries in Acute Coronary Syndrome (GUSTO IV-ACS)
trial (35), in which the serum troponin results did not
predict benefit from medical therapy with abciximab.
As noted earlier, the results of serum troponin testing
generally identified those patients who benefited the most
from invasive management in the TACTICS TIMI-18
study (18,20,36). These results echoed those from the
FRISC-II study, which suggested that the benefits of early
Table 5. American College of Cardiology/American Heart
Association Unstable Angina/Non–ST-Segment Elevation
Myocardial Infarction Guidelines: Recommendations for
Patients Who May Benefit From Early Aggressive Management
Clinical Factors Predicting Risk in the NSTE ACS
History
Frequent angina
Prior history of angina
Prolonged/Ongoing (20 min) angina
Age  65 years
Prior aspirin use
Prior beta-blocker use
Prior revascularization
Diabetes mellitus
Three risk factors for CAD (high cholesterol, plus family history or
ongoing tobacco use)
Physical
Signs of heart failure (including S3 gallop, elevated neck veins,
pulmonary rales)
Hypotension
Laboratory
ECG
ST-segment depression
Transient ST-segment elevation
Deep T-wave inversions (particularly during pain)
Cardiac markers
Elevated serum troponin I or T and/or creatine kinase-MB
J Am Coll Cardiol 2000;36:970–1062. Copyright © 2002 by the American College
of Cardiology and American Heart Association, Inc. Permission granted for one-time
use.
Data also derived from Elsevier Science (Am J Cardiol 2000;86:713–7; Am J
Cardiol 1996;78:35–40; Lancet 1999;354:1757–62; N Engl J Med 1999;340:1623–9;
Circulation 1998;97:2386–95; Lancet 2001;357:1915–21; J Thromb Thrombolysis
2001;11:211–5; J Am Coll Cardiol 2001;38:979–86; Eur Heart J 1999;20:1572–8.
Permission to use data from Lippincott, Williams and Wilkins; Circulation 1998;97:
2386–95; Circulation 1999;100:1509–14; Circulation 1999;100:1609–15.
CAD  coronary artery disease; ECG  electrocardiogram; MB  myocardial
band; NSTE ACS  non-ST-segment Elevation Acute Coronary Syndrome.
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invasive management were particularly strong for those with
elevated serum troponins (37,38).
The mechanism of GP IIb/IIIa benefit (with or without
early invasive management) among patients with elevated
troponins remains speculative. It may relate to the fact that
patients with elevated serum troponins appear to have
higher-risk coronary anatomy, including more extensive
coronary artery disease, as well as a significantly higher
prevalence of intracoronary thrombi and worse epicardial
blood flow rates present at the time of angiography com-
pared to those without elevated troponin levels (37,39). In
these patients, the use of aggressive platelet receptor antag-
onism is thought to be accompanied by reductions in
coronary thrombosis, improved plaque stability, and de-
creased amounts of distal “microembolism” of platelet-rich
debris to the distal microvasculature (with consequent re-
ductions in myocardial injury). The fact that angiographic
substudies from CAPTURE and PRISM-PLUS both dem-
onstrated significant reductions in intracoronary thrombi
with abciximab or tirofiban treatment (with concomitant
improvements in TIMI angiographic flow rates) lends
credence to this hypothesis (40,41). Similarly, an analysis
from PRISM-PLUS by Januzzi and colleagues (21) dem-
onstrated significant reductions in serum troponin I release
among ACS patients treated with tirofiban compared to
those treated with heparin alone. The decrease in troponin
levels correlated with reductions in intracoronary thrombi.
RISK STRATIFICATION
High-risk patients. High-risk patients with NSTE ACS
(Fig. 5) who clearly warrant catheterization and early
revascularization include those with rest angina with ST-
segment depression and/or elevated serum concentrations of
cardiac markers of ischemic injury (creatine kinase-
myocardial band [CK-MB] isoenzyme, troponin, myoglo-
bin). Those who have rest angina with hemodynamic
instability, heart failure, or an ejection fraction 40%, and
those with rest angina and prior revascularization (PCI or
CABG) should be sent to the catheterization laboratory
with revascularization as indicated.
Intermediate-risk patients. Patients with NSTE ACS at
an intermediate level of risk are likely to benefit from cathe-
terization and early revascularization. This subset includes
patients with Canadian Cardiovascular Society class III or IV
angina within the previous two weeks, those with diabetes
mellitus, and those who have deep T-wave inversions in more
than five leads and who have chest discomfort or pain.
Low-risk patients. Patients with NSTE ACS who are not
likely to benefit from catheterization or early revasculariza-
tion include those with Canadian Cardiovascular Society
class I or II angina, normal or nonspecific electrocardiogram
changes, T-wave inversion without ST-segment depression,
and biochemical markers that are negative for CK-MB or
troponin levels.
CLINICAL IMPLICATIONS
The current data support the following conclusions and
caveats:
Table 6. Summary Detailing the Benefits of Glycoprotein IIb/
IIIa Receptor Antagonists Among Troponin-Positive Patients in
Various Clinical Trials
Trial
Event Rates
Risk
ReductionPlacebo Treatment
PRISM 13.7% 3.5% 74%
PARAGON-B 19.0% 11.0% 42%
CAPTURE 19.6% 5.8% 71%
PRISM PLUS 20.6% 3.6% 83%
CAPTURE Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to
standard treatment trial; PARAGON  Platelet IIb/IIIa Antagonism for the
Reduction of Acute coronary syndrome events in a Global Organization Network;
PRISM-PLUS  Platelet Receptor Inhibition for Ischemic Syndrome Management
in Patients Limited by Unstable Signs and Symptoms trial.
Adapted with permission from the author and Kluwer Publishing; J Thromb
Thrombolysis 2001;11:211–5.
Figure 5. Flow diagram of a proposed risk-stratification algorithm for patients with non–ST-segment elevation acute coronary syndromes. ASA  aspirin;
ECG  electrocardiogram; GP IIb/IIIa  glycoprotein platelet IIb/IIIa inhibitor; Hx  history; LMWH  low-molecular-weight heparin; PCI 
percutaneous coronary intervention; PE physical exam; STTWA ST-T-wave abnormalities; TW T-waves; UFH unfractionated heparin. Derived
from Boden WE, McKay R. Optimal treatment of acute coronary syndromes—an evolving strategy. N Engl J Med 2001;344:1939–42.
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WHO BENEFITS FROM EARLY PCI? Tailoring treatment to
the level of risk remains a sound and proven approach to
management. The FRISC-II and TACTICS TIMI-18
studies support the utility of troponin T in risk stratification,
although this is based on retrospective analysis. High-risk
patients who are biomarker positive or have ST-segment
depression are likely to benefit from a strategy of early
revascularization. Low-risk patients are not likely to benefit
from early revascularization, which accounts for 15% to 40%
of all patients (3,4,15,18).
WHEN IS THE OPTIMAL TIME TO INTERVENE? The optimal
timing of PCI in the setting of intensive medical therapy
remains ill defined. The FRISC-II study supports an
interval of four to six days, but this is impractical according
to current North American practice standards. The TAC-
TICS TIMI-18 trial provides data to support this approach
between two to three days’ postevent. There are no data
from within 24 h of symptom-onset.
WHAT FACTORS ARE AT PLAY? Aggressive antiplatelet, an-
tithrombin, and anti-ischemic therapy may be as important
as revascularization. In FRISC-II, intervention was associ-
ated with early hazard, with the survival curves crossing over
between months 1 and 6. This phenomenon was not
observed in the TACTICS TIMI-18 study, prompting the
hypothesis that early hazard might be a consequence of
inadequate platelet inhibition. Indeed, pharmacotherapy
with GP IIb/IIIa platelet inhibition and LMWH may
reduce clinical events whether an early invasive or early
conservative strategy is followed.
WHY DO PATIENTS BENEFIT? Plaque passivation may be
pivotal to optimizing benefits of PCI and CABG. With the
“routine invasive” strategy, late clinical benefit may negate
early hazard, especially with more complete platelet and
thrombin inhibition. The more widespread use of intracoro-
nary stents, coupled with aggressive, multifaceted medical
therapy that includes antiplatelet, antithrombin, and anti-
ischemic therapy, is likely critical to achieving optimized
clinical outcomes.
Conclusions. Risk stratification makes as much sense in
2003 as it did 30 years ago because NSTE ACS is
heterogeneous, with a spectrum of risk ranging from low to
high. The important findings of the FRISC-II, TACTICS
TIMI-18, and RITA-3 trials demonstrate significantly
improved clinical outcomes among intermediate- to high-
risk patients, notably those with positive biomarker and/or
ST-segment depression. For NSTE ACS patients who are
clinically stable and do not exhibit these high-risk features,
stress myocardial perfusion imaging, preferably symptom-
limited exercise-induced imaging, should clearly delineate
high- and intermediate-risk subgroups.
Aggressive pharmacologic therapy is indicated in all
patients. This includes use of aspirin, UFH or LMWH
(especially enoxaparin), and anti-ischemic therapy (intrave-
nous nitroglycerin, beta-blockers and/or calcium antago-
nists), with appropriate secondary prevention (statins and
angiotensin-converting enzyme inhibitors). The GP IIb/
IIIa receptor antagonists should likely be reserved for the
intermediate- to high-risk patient, with either abciximab or
eptifibatide for patients who are undergoing a PCI, or
tirofiban for patients who are first being stabilized clinically
in the coronary care unit. Clopidogrel, coupled with aspirin,
will now likely become standard therapy in all NSTE ACS
patients, based on the results of the CURE Trial (14).
Finally, tailoring therapy to risk level is essential for
optimizing efficacy and cost-effectiveness in this heteroge-
neous group of patients. Use of an interventional approach
in intermediate- to high-risk patients and a noninvasive,
ischemia-guided approach in initially low-risk patients is
both rational and evidence-based.
Reprint requests and correspondence: William E. Boden, Hart-
ford Hospital, 80 Seymour St., Jefferson Building 722, Hartford,
Connecticut 06102. E-mail: wboden@harthosp.org.
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